Virtual Incision Gets OK From FDA for Clinical Studies on Bowel Resection Procedures

Surgical robot maker Virtual Incision’s MIRA platform weighs 2 lb. and is designed to be more portable than traditional systems.

Virtual Incision

Virtual Incision is among several surgical companies going through the FDA process.
Virtual Incision announced that the FDA has granted it an Investigational Device Exemption to complete research on how its robot-assisted surgery platform can aid bowel resection procedures.

Robotic-assisted surgery platform maker Virtual Incision Corp. today announced the U.S. Food and Drug Administration has approved an Investigational Device Exemption supplement to complete the final stage of its clinical study analyzing the MIRA platform in bowel-resection procedures.

The approval was supported by a favorable interim clinical study report on the safety profile of MIRA, said the company.

MIRA platform miniaturizes surgical process

Lincoln, Neb.-based Virtual Incision said its MIRA Platform offer the benefits of robot-assisted surgery (RAS) during abdominal procedures without the logistical inefficiencies of traditional mainframe robotics.

Virtual Incision's Surgeon Console Source: Virtual Incision 

“MIRA was created to address the limitations of traditional robotic-assisted mainframe machines,” said John Murphy, president and CEO of Virtual Incision. “We miniaturized and simplified MIRA to make it more accessible, easy to use, and easy to adopt.”

“Completing the final stage of our clinical study will be a key milestone along MIRA’s regulatory pathway, and we will continue to focus on clinical excellence to best support the innovation we provide to patients and surgeons,” he added.

The device weighs only 2 lb. and can be used in any operating room – a dedicated mainframe room is unnecessary, the company said.  

With its drape- and dock-free design and portability, MIRA is quick to set up, clean up, and move in between cases, enabling an increased robotic-assisted surgery caseload, claimed Virtual Incision.

On the right track

The IDE supplement approval puts Virtual Incision on track to obtain the clinical evidence needed to bring innovation to the soft tissue surgical robotics industry, the company said.  

Results of the completed study will support MIRA’s upcoming FDA “De Novo” application for market authorization.

The first cases of the study were completed at Bryan Medical Center in Lincoln, Neb., by Dr. Michael Jobst and Dr. Kelly Krier, and at Lankenau Medical Center in Wynnewood, Pa., by Dr. John Marks and Dr. Henry Schoonyoung.

“Our clinical experience has been extremely positive so far,” said Dr. Jobst, the first surgeon in the world to operate with the device. “I was able to perform 100% of the dissection with MIRA in all of my cases.”

“We have also been pleased with its accessibility and efficiency,” he said. “I operated on eight patients in five different operating rooms, and that’s something that’s just not possible with mainframe RAS platforms. MIRA has the potential to bring the benefits of minimally invasive surgery to more patients, and that’s truly exciting.”

“These are the features that will allow surgeons to treat more patients each day,” noted Jobst. “It is encouraging to see MIRA demonstrating the potential to help surgeons perform simplified robotic procedures safely and precisely.”

In November 2021, Virtual Incision raised $46 million in Series C funding.

A look at the Virtual Incision platform.

Email Sign Up

Get news, papers, media and research delivered
Stay up-to-date with news and resources you need to do your job. Research industry trends, compare companies and get market intelligence every week with Robotics 24/7. Subscribe to our robotics user email newsletter and we'll keep you informed and up-to-date.

Virtual Incision

Virtual Incision is among several surgical companies going through the FDA process.

Robot Technologies